癌症患者分子靶向治疗中肠毒性的影像学特征。
Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients.
机构信息
Department of Imaging, Dana-Farber Cancer Institute, Boston, MA, USA.
出版信息
Br J Radiol. 2012 Oct;85(1018):1420-6. doi: 10.1259/bjr/19815818. Epub 2012 Jun 6.
Abstract
Molecular targeted therapies are becoming ubiquitous in cancer treatment. These drugs may cause gastrointestinal toxicities including perforation, pneumatosis, enteritis, colitis and fistula formation. Knowledge of these complications and their management enables early radiological identification and appropriate intervention, reducing patient morbidity and mortality.
摘要
分子靶向治疗在癌症治疗中变得无处不在。这些药物可能会引起胃肠道毒性，包括穿孔、气肿、肠炎、结肠炎和瘘管形成。了解这些并发症及其处理方法可以实现早期放射学识别和适当的干预，从而降低患者的发病率和死亡率。
相似文献
1
Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients.
Br J Radiol. 2012 Oct;85(1018):1420-6. doi: 10.1259/bjr/19815818. Epub 2012 Jun 6.
2
Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management.
AJR Am J Roentgenol. 2012 Dec;199(6):1259-65. doi: 10.2214/AJR.12.8782.
3
Reply: To PMID 23169717.
AJR Am J Roentgenol. 2013 Aug;201(2):W370. doi: 10.2214/AJR.13.10818.
4
Portal venous gas secondary to molecular targeted therapy.
AJR Am J Roentgenol. 2013 Aug;201(2):W368-9. doi: 10.2214/AJR.13.10770.
5
Gastrointestinal complications following renal transplantation.
Radiology. 1975 Oct;117(1):37-43. doi: 10.1148/117.1.37.
6
Education and imaging. Gastrointestinal: Benign cause for pneumatosis intestinalis and portomesenteric venous gas.
J Gastroenterol Hepatol. 2009 May;24(5):927. doi: 10.1111/j.1440-1746.2009.05886.x.
7
Pneumatosis Intestinalis After Molecular-Targeted Therapy.
World Neurosurg. 2019 May;125:312-315. doi: 10.1016/j.wneu.2019.01.225. Epub 2019 Feb 11.
8
Necrotizing colitis complicating necrotized pancreatitis: look out for intestinal pneumatosis.
JBR-BTR. 2013 Jan-Feb;96(1):19-21. doi: 10.5334/jbr-btr.169.
9
Pneumatosis cystoides intestinalis: case report and review of literature.
Clin J Gastroenterol. 2020 Feb;13(1):31-36. doi: 10.1007/s12328-019-00999-3. Epub 2019 Jun 3.
10
Pneumatosis intestinalis and intestinal perforation in a case of multisystem inflammatory syndrome in children.
BMJ Case Rep. 2021 Apr 22;14(4):e241688. doi: 10.1136/bcr-2021-241688.
引用本文的文献
1
Imaging of acute small bowel pathologies in oncology patients in the ER part II: the role of computed tomography (CT) in detection of treatment-related small bowel complications.
Emerg Radiol. 2025 Apr 12. doi: 10.1007/s10140-025-02342-5.
2
Imaging of abdominopelvic oncologic emergencies.
Abdom Radiol (NY). 2024 Mar;49(3):823-841. doi: 10.1007/s00261-023-04112-8. Epub 2023 Nov 28.
3
Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects.
J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3824-e3829. doi: 10.1210/clinem/dgac337.
4
Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review.
Cancers (Basel). 2022 Mar 25;14(7):1666. doi: 10.3390/cancers14071666.
5
CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor-specific therapies.
Abdom Radiol (NY). 2021 May;46(5):2219-2235. doi: 10.1007/s00261-020-02837-4. Epub 2020 Nov 2.
6
Bowel Perforation in the Emergency Department Related to Bevacizumab Therapy and Recurrent Ovarian Cancer.
Clin Pract Cases Emerg Med. 2020 Mar 27;4(2):227-229. doi: 10.5811/cpcem.2020.1.45374. eCollection 2020 May.
7
Diarrhea Concealing a Duodenal-Cecal Fistula Secondary to Appendiceal Mucinous Neoplasm.
ACG Case Rep J. 2017 Jan 4;4:e3. doi: 10.14309/crj.2017.3. eCollection 2017.
8
Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists.
Korean J Radiol. 2017 Jan-Feb;18(1):6-17. doi: 10.3348/kjr.2017.18.1.6. Epub 2017 Jan 5.
9
Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report.
World J Surg Oncol. 2016 Jun 29;14(1):175. doi: 10.1186/s12957-016-0926-1.
10
Update on the role of imaging in management of metastatic colorectal cancer.
Radiographics. 2014 Nov-Dec;34(7):1908-28. doi: 10.1148/rg.347130090.
本文引用的文献
1
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
J Clin Oncol. 2011 Jun 20;29(18):2582-9. doi: 10.1200/JCO.2010.30.7678. Epub 2011 May 16.
2
Everolimus- and temsirolimus-associated enteritis: report of three cases.
J Clin Oncol. 2011 May 10;29(14):e404-6. doi: 10.1200/JCO.2010.33.5984. Epub 2011 Feb 28.
3
Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences.
J Comput Assist Tomogr. 2011 Jan-Feb;35(1):86-90. doi: 10.1097/RCT.0b013e3181fce2cb.
4
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
Clin Colorectal Cancer. 2010 Dec;9(5):297-304. doi: 10.3816/CCC.2010.n.043.
5
Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.
Angiogenesis. 2011 May;14(2):135-41. doi: 10.1007/s10456-010-9197-6. Epub 2010 Dec 29.
6
Improved survival with ipilimumab in patients with metastatic melanoma.
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
7
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Invest New Drugs. 2011 Oct;29(5):1090-3. doi: 10.1007/s10637-010-9458-7. Epub 2010 Jun 5.
8
Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
Gynecol Oncol. 2010 Jul;118(1):47-51. doi: 10.1016/j.ygyno.2010.01.011. Epub 2010 Apr 10.
9
Managing bevacizumab-related toxicities in patients with colorectal cancer.
J Support Oncol. 2009 Nov-Dec;7(6):245-51.
10
Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.
Lancet Oncol. 2009 Jun;10(6):559-68. doi: 10.1016/S1470-2045(09)70112-3.
Zotero 插件